Status:
TERMINATED
Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Tobacco Dependence
Eligibility:
All Genders
13-17 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine: 1) the short-term clinical efficacy and safety of bupropion for helping adolescent tobacco smokers quit, and 2) The role of withdrawal symptoms in the mainte...
Detailed Description
This 10-week study consists of an unassisted (pretrial) acute tobacco withdrawal (AW) phase and a 7-week randomized double-blind placebo-controlled trial of bupropion (300 mg/day) for tobacco dependen...
Eligibility Criteria
Inclusion
- More than 100 lbs
- IQ greater than 80
- General good health
- Not pregnant
- Non-Smoker: No cigarettes in last 6 months, less than 5 in lifetime
- Smokers: Smoke more than 6 cigarettes per day for at least 6 months
Exclusion
- Cardiac, Central Nervous System (CNS) or severe psychiatric disorder
- Psychoactive medications (including nicotine replacement)
- Substance use disorder
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00248118
Start Date
January 1 2005
End Date
May 1 2008
Last Update
September 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Teen Tobacco Addiction Research Clinic, NIDA Intramural Research Program
Baltimore, Maryland, United States, 21224